Madrigal Pharmaceuticals
MDGL
379.10
-17.64
-4.45%
Madrigal Pharmaceuticals
US · MDGL
#1355 by market cap
Listed 2016
379.10
-17.64
-4.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
D-
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Wolfe Research moved from Hold to Buy on 2026-08-04.
Analyst consensus 9 analysts
Buy
Avg price target 702.33 +85.3%
Price target rangecurrent 379.10
Low479.00
Avg702.33
High962.00
Buy 89%
Hold 11%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-12 | H.C. Wainwright | -- | Buy | 620.00 |
| 2026-11-09 | BofA Securities | -- | Hold | 479.00 |
| 2026-11-04 | CCORF | -- | Buy | 633.00 |
| 2026-11-04 | Wells Fargo | -- | Buy | 685.00 |
| 2026-11-04 | BofA Securities | -- | Hold | 479.00 |
| 2026-11-04 | Truist Financial | -- | Buy | 743.00 |
| 2026-11-04 | Citi | -- | Buy | 760.00 |
| 2026-11-04 | H.C. Wainwright | -- | Buy | 620.00 |
| 2026-11-04 | Barclays | -- | Buy | 962.00 |
| 2026-11-03 | Citi | -- | Buy | 760.00 |
| 2026-10-29 | CCORF | -- | Buy | 612.00 |
| 2026-10-19 | BofA Securities | -- | Hold | 533.00 |
| 2026-10-16 | Wells Fargo | -- | Buy | 685.00 |
| 2026-10-15 | UBS | -- | Buy | 735.00 |
| 2026-10-14 | UBS | -- | Buy | 735.00 |
| 2026-10-12 | Wells Fargo | -- | Buy | 685.00 |
| 2026-10-08 | H.C. Wainwright | -- | Buy | 620.00 |
| 2026-09-30 | Barclays | -- | Buy | 962.00 |
| 2026-09-24 | Goldman Sachs | -- | Buy | 704.00 |
| 2026-09-23 | Citi | -- | Buy | 725.00 |
| 2026-08-11 | CCORF | -- | Buy | 612.00 |
| 2026-08-04 | Wolfe Research | -- | Buy | 605.00 |
| 2026-08-03 | Barclays | -- | Buy | 962.00 |
| 2026-07-31 | Truist Financial | -- | Buy | 709.00 |
| 2026-07-31 | H.C. Wainwright | -- | Buy | 620.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-04 | Wolfe Research | Hold → Buy | 605.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-03 | -- | ±13.90% | -8.08% (in line) |
| 2026/Q2 | 2026-07-30 | -- | ±11.57% | -9.83% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±9.99% | +7.42% (in line) |
| 2025/Q4 | 2026-02-19 | -- | ±6.71% | -11.11% (beat) |
| 2025/Q3 | 2025-11-04 | -- | ±13.94% | +7.83% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±10.86% | +8.59% (in line) |
| 2025/Q1 | 2025-05-01 | -- | ±13.18% | -1.86% (in line) |
| 2024/Q4 | 2025-02-26 | -- | ±15.36% | +14.99% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±18.10% | +20.10% (beat) |
| 2024/Q2 | 2024-08-07 | -- | ±13.17% | -12.18% (in line) |
| 2024/Q1 | 2024-05-07 | -- | ±9.55% | -7.48% (in line) |
| 2022/Q1 | 2022-05-09 | -- | ±16.92% | -10.14% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Madrigal Pharmaceuticals discussion 0 comments